Allergy is the most prevalent and the fastest growing chronic condition in the industrialized world with over 300 million people affected. The allergic population has doubled in western countries over the past 20 years and 20 to 30% of the population of industrialized countries suffers from various forms of allergic diseases (asthma, rhinitis, urticaria, food allergies) impairing their quality of life and often leading to work disability.

Anergis discovers and develops Breakthrough Allergy Vaccines

• derived from the proprietary scientific concept of “Contiguous Overlapping Peptides” 
• providing an ultra-fast  and safe method of Allergen Specific ImmunoTherapy (SIT)
• with established long term immunological effects
• fully compliant with new SIT pharmaceutical regulations